NCIL

NEPHRO CARE INDIA LIMITED
(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)
CIN: L85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,
Sai Complex, North 24 Parganas, Kolkata - 700098, West Bengal, India.
Web: **https://www.nephrocareindia.com/**
Email id: cs@nephrocareindia.com / Mobile No. 80170 10197

Date: 29th August 2026

To,
The National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051

Subject: Clarification regarding Standalone and Consolidated Financial Results for the quarter ended 30 June 2026

Ref: NSE communication dated 28th August 2026 – Clarification for Financial Results – Nephro Care India Limited

Dear Sir/Madam,

This is with reference to the communication received from the Exchange with respect to the financial results submitted by **Nephro Care India Limited ("the Company")** on **7 August 2026**, wherein the Exchange has observed that the figures reported under the Standalone and Consolidated Financial Results are the same and has sought clarification in this regard.

We hereby submit the following clarification for your kind consideration:

1. **Incorporation of subsidiary**

   Vivacity Multiple Ventures Private Limited ("Vivacity") was incorporated on **18 December 2025** as a subsidiary of the Company.

   Since its incorporation, Vivacity has, as on **30 June 2026**, undertaken only activities relating to its incorporation, statutory compliances and other preliminary/pre-operative matters. The subsidiary **has not commenced its commercial operations** as on the reporting date.

2. **Financial position of the subsidiary**

   During the period from incorporation up to **30 June 2026**, Vivacity has not generated any revenue from operations or any other income.

   The expenditure incurred during the said period primarily relates to incorporation, statutory and other pre-operative activities and has been duly accounted for in the books of the subsidiary in accordance with the applicable accounting framework and the accounting treatment followed in the financial statements.

   Consequently, the financial results of Vivacity for the quarter ended **30 June 2026** reflect:
   - **Total Income – Rs. NIL lakhs**
   - **Profit After Tax – Rs. NIL lakhs**

3. **Consolidation of the subsidiary**

NEPHRO CARE INDIA LIMITED
(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)
CIN: L85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,
Sai Complex, North 24 Parganas, Kolkata - 700098, West Bengal, India.
Web: https://www.nephrocareindia.com/
Email id: cs@nephrocareindia.com / Mobile No. 80170 10197

The Company has duly considered Vivacity for the purpose of preparation of the **Consolidated Financial Results** for the quarter ended 30 June 2026.

The fact that the subsidiary has not commenced commercial operations and has reported NIL income and NIL profit after tax does not mean that the subsidiary has been excluded from consolidation. Rather, its financial information has been duly considered in the preparation of the Consolidated Financial Results.

This is also corroborated by **Point No. 6 of the Auditor's Report on the Consolidated Financial Results**, which specifically states that the interim financial information/results of the subsidiary have been considered in the Consolidated Financial Results and that the subsidiary reported **Total Income of Rs. NIL lakhs and Profit After Tax of Rs. NIL lakhs for the quarter ended 30 June 2026**.

4. Reason for identical figures in the financial results

The principal reason for the **Standalone and Consolidated figures of the Statement of Profit and Loss being identical** for the quarter ended 30 June 2026 is that the subsidiary had:
a. not commenced commercial operations;
b. no revenue from operations;
c. no other income; and
d. no profit after tax during the reporting quarter.

Accordingly, the consolidation of the subsidiary has **not resulted in any change to the corresponding income and profit/loss figures reported by the Company for the quarter**.

It is therefore submitted that the similarity of the figures in the Standalone and Consolidated Financial Results is **a consequence of the underlying financial position and activities of the subsidiary during the reporting period and is not due to non-consolidation of the subsidiary**.

5. Compliance with applicable accounting and regulatory requirements

The Company has prepared and submitted the Standalone and Consolidated Financial Results having regard to the applicable provisions of the **Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Schedule III and the applicable Indian Accounting Standards**, as applicable to the Company.

The financial results are required to be prepared in accordance with the applicable accounting framework, and SEBI's prescribed financial-results framework requires the relevant line items of the Statement of Profit and Loss to be presented in accordance with Schedule III.

The Company has also ensured that the Consolidated Financial Results incorporate the financial information of its subsidiary, notwithstanding the fact that the subsidiary had no commercial activity or income during the quarter.

6. Clarification regarding the Exchange's observation

In view of the above, we respectfully submit that the **identical figures in the Standalone and Consolidated Financial Results should not be construed as non-compliance with the requirement for preparation/submission of Consolidated Financial Results**.

The similarity arises solely because the subsidiary was in its pre-operative stage and had **NIL income and NIL profit after tax** during the quarter ended 30 June 2026.

The Company acknowledges the Exchange's observation regarding presentation of the financial results and confirms that the financial statements/results have been prepared based on the financial information available from the Company and its subsidiary and in accordance with the applicable accounting and regulatory requirements.

7. Request

In view of the foregoing clarification and the fact that the subsidiary's interim financial information has been duly considered for consolidation, we respectfully request the Exchange to **take the above clarification on record and treat the observation as duly clarified**.

The Company remains committed to maintaining the highest standards of financial reporting, transparency and regulatory compliance and shall continue to ensure that its financial results are submitted in the prescribed format and within the applicable regulatory timelines.

Thanking you,
Yours faithfully,
For Nephro Care India Limited

SOUGATA SENGUPTA
Digitally signed by SOUGATA SENGUPTA
Date: 2026.08.29 11:00:50 +05'30'

Sougata Sengupta
Company Secretary